269. Pyogenic arthritis Clinical trials / Disease details

Clinical trials : 24 / Drugs : 30 - (DrugBank : 12) / Drug target genes : 15 - Drug target pathways : 105

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03311464 (ClinicalTrials.gov)	October 27, 2017	12/10/2017	A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan	A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan	Pyoderma Gangrenosum	Drug: adalimumab	AbbVie	NULL	Completed	18 Years	N/A	All	22	Phase 3	Japan
2	NCT00730717 (ClinicalTrials.gov)	May 2009	4/8/2008	Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum	Multi Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum	Pyoderma Gangrenosum	Drug: Humira	Wright State University	Stanford University;Wake Forest University Health Sciences	Withdrawn	18 Years	N/A	All	0	Phase 2	United States
3	NCT00690846 (ClinicalTrials.gov)	July 2007	2/6/2008	Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum	A Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37)	Pyoderma Gangrenosum	Drug: adalimumab	Wake Forest University Health Sciences	NULL	Withdrawn	18 Years	N/A	All	0	Phase 2	United States